Macitentan/tadalafil

Last updated

Macitentan/tadalafil
Combination of
Macitentan Endothelin receptor antagonist
Tadalafil Phosphodiesterase 5 (PDE5) inhibitor
Clinical data
Trade names Opsynvi
AHFS/Drugs.com Monograph
MedlinePlus a624029
License data
Pregnancy
category
  • Not recommended
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Macitentan/tadalafil, sold under the brand name Opsynvi, is a fixed dose combination medication used for the treatment of pulmonary arterial hypertension. [3] [6] It contains macitentan, an endothelin receptor antagonist (ERA); and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. [3]

Contents

Macitentan/tadalafil was approved for medical use in Canada in October 2021, [7] in the United States in March 2024, [8] [9] and in the European Union in September 2024. [4] [5]

Medical uses

Macitentan/tadalafil is indicated for the chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults of WHO functional class (FC) II-III. [3]

Adverse effects

Macitentan/tadalafil may cause harm to the fetus. [3]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yuvanci, intended for the treatment of pulmonary arterial hypertension (PAH). [4] The applicant for this medicinal product is Janssen-Cilag International NV. [4] The combination was authorized for medical use in the European Union in September 2024. [4] [5]

References

  1. ↑ "OPSYNVI (Janssen-Cilag Pty Ltd)". Therapeutic Goods Administration (TGA). Commonwealth of Australia.
  2. ↑ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada . 3 August 2022. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
  3. 1 2 3 4 5 "Opsynvi- macitentan and tadalafil tablet, film coated". DailyMed. 22 March 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.
  4. 1 2 3 4 5 "Yuvanci EPAR". European Medicines Agency (EMA). 25 July 2024. Retrieved 27 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. 1 2 3 "Yuvanci PI". Union Register of medicinal products. 30 September 2024. Retrieved 4 March 2025.
  6. ↑ Saggar R, Rahhali N, Senatore A, Sandros M, Lopez D, Gomez Rendon G, et al. (2024). "Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension: Results of a Systematic Literature Review". American Journal of Respiratory and Critical Care Medicine. 209: A2149. doi:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A2149.
  7. ↑ "Opsynvi (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)". Johnson & Johnson (Press release). 15 October 2021. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
  8. ↑ "Approval Letter: Opsynvi (macitentan and tadalafil)" (PDF). U.S. Food and Drug Administration. Archived from the original (PDF) on 25 March 2024. Retrieved 25 March 2024.
  9. ↑ "U.S. FDA Approves Opsynvi (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)". Johnson & Johnson (Press release). 22 March 2024. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.